IDEAS home Printed from https://ideas.repec.org/a/abf/journl/v48y2023i4p39935-39946.html
   My bibliography  Save this article

Comparison of China Domestic Alfentanil Hydrochloride with Sufentanil Citrate in Elderly Patients- A TripleBlinded, Randomized Controlled Non-Inferiority Trial

Author

Listed:
  • Quan Ren

    (Department of Anesthesiology, Zhongda Hospital, Southeast University, China)

Abstract

China domestic alfentanil hydrochloride (Yichang Human Well Pharmaceutical Co. Ltd., Yichang, China) is the first alfentanil pharmaceutical preparations produced in China, which has been approved for clinically use by the China Food and Drug Administration since Match, 2020. Its clinical pharmacological characteristic needs to be validated in clinical practice. The trial was conducted to compare the efficiency and adverse effects of China domestic alfentanil hydrochloride with sufentanil citrate (positive control) in elderly patients during perioperative period.

Suggested Citation

  • Quan Ren, 2023. "Comparison of China Domestic Alfentanil Hydrochloride with Sufentanil Citrate in Elderly Patients- A TripleBlinded, Randomized Controlled Non-Inferiority Trial," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 48(4), pages 39935-39946, February.
    • Handle: RePEc:abf:journl:v:48:y:2023:i:4:p:39935-39946
    DOI: 10.26717/BJSTR.2023.48.007687
    as

    Download full text from publisher

    File URL: https://biomedres.us/pdfs/BJSTR.MS.ID.007687.pdf
    Download Restriction: no
    File URL: https://biomedres.us/fulltexts/BJSTR.MS.ID.007687.php
    Download Restriction: no
    File URL: https://libkey.io/10.26717/BJSTR.2023.48.007687?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:abf:journl:v:48:y:2023:i:4:p:39935-39946. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Angela Roy (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.